EA Perez

Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831

Patrick C. Roche, VJ Suman, Robert B. Jenkins et al. · JNCI Journal of the National Cancer Institute · 2002 · 402 citations · Full text

Medicine, Oncology, Pathology +17

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

Sara A. Hurvitz, L. Dirix, Judit Kocsis et al. · European Journal of Cancer · 2011 · 54 citations

Medicine, Oncology, Pharmacology +17

Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.

James A. Bonner, Jeff A. Sloan, Kendrith M. Rowland et al. · PubMed · 2000 · 47 citations

Medicine, Oncology, Cancer Pharmacology +13

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

Véronique Dièras, John A. Glaspy, Adam Brufsky et al. · European Journal of Cancer Supplements · 2009 · 44 citations

Medicine, Oncology, Pharmacology +16

Results of an analysis of cardiac function in 2,812 patients treated with lapatinib

EA Perez, Julie Byrne, Isaac W. Hammond et al. · Journal of Clinical Oncology · 2006 · 40 citations

Medicine, Oncology, Pharmacology +17